TABLE 5.

Geographic variation in the in vitro susceptibilities of C. albicans and C. glabrata to fluconazole and voriconazole as determined by CLSI disk diffusion testing: ARTEMIS DISK Global Surveillance Program, 2001 to 2003^a,b

Region/country	Antifungal agent	Susceptibility
		C. albicans			C. glabrata
		n	%S	%R	n	%S	%R
Asia-Pacific
Australia	Fluconazole	207	96.6	2.4	74	58.1	16.2
	Voriconazole	207	99.0	1.0	74	77.0	9.5
China	Fluconazole	1,071	97.1	1.7	307	74.9	13.4
	Voriconazole	1,055	98.7	0.7	307	83.4	8.5
India	Fluconazole	60	70.0	23.3	6	100.0	0.0
	Voriconazole	60	78.3	20.0	6	100.0	0.0
Malaysia	Fluconazole	4,327	99.1	0.3	623	34.0	24.1
	Voriconazole	3,602	99.5	0.0	518	59.5	0.8
South Africa	Fluconazole	3,324	99.4	0.3	355	49.6	21.1
	Voriconazole	3,286	99.9	0.1	333	73.3	3.0
South Korea	Fluconazole	1,928	99.5	0.2	49	83.7	12.2
	Voriconazole	1,848	99.7	0.3	47	83.0	10.6
Taiwan	Fluconazole	1,395	95.8	2.7	352	75.6	12.2
	Voriconazole	1,389	98.5	1.0	349	84.0	4.9
Thailand	Fluconazole	290	97.6	1.4	93	71.0	5.4
	Voriconazole	289	98.6	1.0	93	92.5	2.2
Europe
Belgium	Fluconazole	1,761	99.5	0.3	224	39.7	42.0
	Voriconazole	1,683	99.7	0.3	216	53.2	18.5
Czech Republic	Fluconazole	2,633	99.6	0.2	429	44.8	27.5
	Voriconazole	2,402	99.9	0.0	412	65.3	8.7
France	Fluconazole	1,149	97.7	1.1	265	77.4	15.1
	Voriconazole	936	99.4	0.4	202	85.1	5.9
Germany	Fluconazole	1,214	94.2	2.8	634	58.5	15.9
	Voriconazole	1,214	98.3	0.8	634	72.6	4.3
Greece	Fluconazole	223	96.4	3.1	66	93.9	4.5
	Voriconazole	223	97.8	2.2	66	95.5	3.0
Hungary	Fluconazole	5,036	98.3	0.7	860	58.4	16.9
	Voriconazole	4,889	99.6	0.3	821	74.2	3.9
Italy	Fluconazole	2,638	97.5	1.8	582	81.3	9.5
	Voriconazole	2,638	99.1	0.5	582	88.5	4.1
Netherlands	Fluconazole	1,815	98.8	1.0	190	76.3	8.9
	Voriconazole	1,815	99.3	0.6	190	87.9	3.7
Norway	Fluconazole	187	98.9	1.1	14	71.4	14.3
	Voriconazole	187	100.0	0.0	14	71.4	14.3
Poland	Fluconazole	476	99.4	0.2	59	86.4	8.5
	Voriconazole	351	99.7	0.3	58	89.7	3.4
Portugal	Fluconazole	754	97.2	2.7	70	87.1	4.3
	Voriconazole	754	98.1	1.7	70	90.0	1.4
Russia	Fluconazole	916	98.8	0.9	64	60.9	20.3
	Voriconazole	906	99.1	0.9	64	79.7	6.3
Slovakia	Fluconazole	1,362	99.0	0.4	155	78.1	4.5
	Voriconazole	1,362	98.6	1.3	155	89.7	1.9
Spain	Fluconazole	2,617	98.5	0.9	321	62.3	24.0
	Voriconazole	2,614	99.5	0.2	321	75.4	7.2
Switzerland	Fluconazole	566	97.9	1.1	144	78.5	9.7
	Voriconazole	565	99.5	0.5	144	83.3	4.2
Turkey	Fluconazole	519	98.3	1.3	17	82.4	11.8
	Voriconazole	475	98.3	1.5	15	100.0	0.0
United Kingdom	Fluconazole	4,340	98.8	0.5	868	68.4	14.2
	Voriconazole	4,055	99.4	0.4	837	77.9	6.0
Middle East
Israel	Fluconazole	12	100.0	0.0	1	100.0	0.0
	Voriconazole	12	100.0	0.0	1	100.0	0.0
Saudi Arabia	Fluconazole	20	100.0	0.0	2	100.0	0.0
	Voriconazole	20	100.0	0.0	2	100.0	0.0
Latin America
Argentina	Fluconazole	1,595	97.6	1.4	335	74.0	14.9
	Voriconazole	1,458	99.5	0.0	318	84.9	4.4
Brazil	Fluconazole	1,401	99.6	0.1	410	94.9	3.9
	Voriconazole	1,288	99.8	0.0	405	96.8	1.0
Colombia	Fluconazole	1,315	91.2	6.1	99	75.8	17.2
	Voriconazole	1,263	94.9	4.0	90	80.0	7.8
Ecuador	Fluconazole	1,169	91.6	4.9	33	60.6	27.3
	Voriconazole	1,093	96.4	0.7	33	66.7	12.1
Mexico	Fluconazole	186	98.4	1.1	15	86.7	13.3
	Voriconazole	179	98.3	1.7	15	73.3	6.7
Venezuela	Fluconazole	550	94.4	2.7	48	29.2	60.4
	Voriconazole	525	96.6	2.5	49	32.7	38.8
North America
Canada	Fluconazole	297	100.0	0.0	117	90.6	5.1
	Voriconazole	297	100.0	0.0	117	95.7	1.7
United States	Fluconazole	2,638	94.8	4.4	1,159	75.9	19.3
	Voriconazole	2,644	97.0	2.2	1,161	82.1	9.7

^aIsolates obtained from 115 institutions in 35 countries.

^bFluconazole and voriconazole disk diffusion testing was performed in accordance with CLSI M44-A. Interpretive breakpoints: S, ≥19 mm (fluconazole), ≥17 mm (voriconazole); R, ≤14 mm (fluconazole), ≤13 mm (voriconazole).